Bismuth-Based Therapy for Helicobacter pylori Infection
First-Line Treatment: Bismuth Quadruple Therapy is the Preferred Regimen
Bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) for 14 days is the preferred first-line regimen for H. pylori eradication in North America, endorsed by the Toronto Consensus, Maastricht V/Florence Consensus, and the American College of Gastroenterology. 1, 2
Standard Dosing Regimen
- Bismuth subsalicylate 262 mg (2 tablets) four times daily 1
- Tetracycline 500 mg four times daily 1, 3
- Metronidazole 500 mg three to four times daily 1, 3
- Proton-pump inhibitor (standard dose) twice daily 1
- Duration: 14 days is mandatory 1, 4
This regimen achieves eradication rates exceeding 85–90% even in regions with dual clarithromycin and metronidazole resistance, because bismuth synergizes with metronidazole to overcome resistance. 1, 4
Why Bismuth Quadruple Therapy Works Despite Resistance
The synergistic effect of bismuth with metronidazole allows this regimen to retain acceptable efficacy against metronidazole-resistant strains. 1 A meta-analysis demonstrated that bismuth significantly increased eradication rates of clarithromycin-resistant strains by 40%, metronidazole-resistant strains by 26%, and dual-resistant strains by 59%. 4 This benefit is only consistently demonstrated with 14-day treatment duration; 7-day courses show no significant advantage. 4
Proton-Pump Inhibitor Selection: Potency Matters
Use high-potency PPIs—esomeprazole or rabeprazole—to maximize eradication rates. 1, 5 Pantoprazole should be avoided because its acid-suppression potency is markedly lower (40 mg pantoprazole ≈ 9 mg omeprazole). 1, 5
PPI Potency Hierarchy (twice daily dosing)
- Rabeprazole 20–40 mg (≈ 36 mg omeprazole) 1, 5
- Esomeprazole 20–40 mg (≈ 32 mg omeprazole) 1, 5
- Lansoprazole 30–45 mg (≈ 27 mg omeprazole) 1
- Omeprazole 40 mg (least preferred acceptable option) 1
PPIs must be taken 30 minutes before meals on an empty stomach, and H₂-receptor antagonists must not be used concurrently because they interfere with PPI activation. 1, 3
Alternative First-Line Regimens
When Bismuth is Unavailable
Concomitant quadruple therapy (PPI + amoxicillin + clarithromycin + metronidazole) for 14 days is acceptable when bismuth is unavailable and local clarithromycin resistance is high. 1 Recent U.S. data show an 89.8% eradication rate. 1, 6
However, the 2022 Annual Review of Medicine now classifies concomitant therapy as "obsolete" because it exposes patients to unnecessary antibiotics that provide no therapeutic benefit when resistance is present. 5 This represents a major shift from earlier guidelines.
Rifabutin Triple Therapy
Rifabutin triple therapy (PPI + amoxicillin + rifabutin 150 mg twice daily) for 14 days is an acceptable empiric alternative for patients without penicillin allergy. 1, 5 Resistance to rifabutin and amoxicillin remains rare (<2%). 7, 1
When Clarithromycin Triple Therapy May Be Used
Clarithromycin-based triple therapy (PPI + clarithromycin + amoxicillin) should only be used when ALL of the following criteria are met: 1
- Local clarithromycin resistance is <15%
- Local eradication rates with this regimen exceed 85%
- The patient has never received a macrolide antibiotic
In most North American settings, clarithromycin resistance reaches 20–30%, making this regimen unsuitable for empiric use. 1
Second-Line (Rescue) Therapy After First-Line Failure
Core Antibiotic Stewardship Principle
Never reuse clarithromycin or levofloxacin if they were part of a previously failed regimen, because resistance develops in >90% of previously treated strains. 7, 1
After Clarithromycin-Containing First-Line Failure
Bismuth quadruple therapy for 14 days is the preferred rescue option, achieving 69.3% eradication in salvage settings. 7, 6
Levofloxacin triple therapy (PPI + amoxicillin + levofloxacin 500 mg daily) for 14 days is an alternative, but susceptibility testing is strongly advised because levofloxacin resistance in North America ranges from 18–24%. 7, 1
After Bismuth Quadruple or Metronidazole-Containing First-Line Failure
Levofloxacin triple therapy for 14 days is recommended, with susceptibility testing strongly considered before use. 7, 1
High-dose dual therapy (high-potency PPI 80 mg twice daily + amoxicillin 2–3 g daily divided 3–4 times) for 14 days achieves approximately 89% eradication in salvage settings. 7, 1, 8
Third-Line (Salvage) Therapy After Two Failures
Culture with antimicrobial susceptibility testing is strongly recommended after second-line failure to guide subsequent therapy. 7, 1
Empiric Options When Susceptibility Data Are Unavailable
Tetracycline-levofloxacin quadruple therapy (PPI + bismuth + tetracycline + levofloxacin) for 14 days achieved 98% eradication versus 69% for levofloxacin-amoxicillin triple therapy in head-to-head trials. 7, 8
High-dose dual therapy (PPI 80 mg twice daily + amoxicillin 2–3 g daily divided 3–4 times) for 14 days. 7, 1
Bismuth quadruple therapy for 14 days if not previously used. 7, 1
Fourth-Line Therapy (After Three or More Failures)
A rifabutin-containing regimen (PPI + amoxicillin + rifabutin 150–300 mg daily) for 14 days should be reserved for patients who have failed at least three prior regimens because of the risk of myelotoxicity. 7, 1 Resistance to rifabutin and amoxicillin remains rare (<2%). 7, 1
Antibiotic Reuse Principles
Never Reuse After Prior Exposure
- Clarithromycin (resistance develops in >90% of previously treated strains) 7, 1
- Levofloxacin (resistance emerges rapidly) 7, 1
May Be Reused
- Metronidazole when combined with bismuth (synergistic effect overcomes resistance) 7, 1, 3
- Amoxicillin (resistance remains <5%) 7, 1
- Tetracycline (resistance remains <5%) 7, 1
Special Populations
Penicillin-Allergic Patients
Bismuth quadruple therapy (tetracycline + metronidazole-based) is the preferred first-line regimen for patients with confirmed penicillin allergy. 1
After first-line failure in penicillin-allergic patients, referral for formal allergy testing is strongly advised because most reported penicillin allergies are not true IgE-mediated reactions. 7, 1 If testing confirms no true allergy, amoxicillin-containing regimens can be used safely at ≥2 g daily divided 3–4 times. 7
Elderly Patients (≥65 Years)
Ten-day bismuth quadruple therapy achieves comparable eradication rates in elderly versus non-elderly patients (89.1% vs. 94.8% per-protocol), with similar adverse event rates. 9 However, compliance may be slightly lower in elderly patients (89.1% vs. 95.4%). 9
Half-dose antibiotic regimens (tetracycline 500 mg twice daily, metronidazole 375 mg twice daily) for 14 days may be considered for patients with risk of drug interactions, but should not be used in patients ≥75 years solely due to age, as eradication rates drop to 74.6%. 10
Treatment Duration: 14 Days is Mandatory
All first-line and rescue regimens must be administered for 14 days to maximize eradication success, reduce retreatment costs, and limit microbiome disruption. 1, 4 The shift from 7–10-day courses reflects declining efficacy amid rising antibiotic resistance. 1
Partial courses of bismuth quadruple therapy diminish the synergistic effect of bismuth with metronidazole and markedly increase the risk of developing resistance. 3
Confirmation of Eradication
A test-of-cure (urea breath test or stool antigen) performed 4–6 weeks after completion of therapy is mandatory to confirm eradication. 7, 1 Proton-pump inhibitors must be stopped 1–2 weeks before testing to avoid false-negative results. 1
Common Pitfalls to Avoid
- Do not use 7–10-day regimens; 14 days is the universal standard. 1, 4
- Do not use clarithromycin empirically unless local resistance is documented <15% and the patient has never received a macrolide. 1
- Do not use levofloxacin as first-line therapy; reserve it for rescue after failure of other regimens. 1
- Do not repeat the same antibiotic combination that previously failed. 7, 1
- Do not use pantoprazole when higher-potency PPIs are available. 1, 5
- Do not prescribe concomitant non-bismuth quadruple therapy as it is now deemed obsolete. 5
- Do not substitute doxycycline for tetracycline in bismuth quadruple therapy, as doxycycline yields significantly inferior outcomes. 5
Key Success Factors
- Use bismuth quadruple therapy as the first-line regimen 1, 2
- Ensure a 14-day treatment duration 1, 4
- Select a high-potency PPI (rabeprazole or esomeprazole) 1, 5
- Confirm eradication after therapy 7, 1
- Avoid reuse of clarithromycin or levofloxacin after prior exposure 7, 1
- Review history of macrolide or metronidazole use before selecting regimens 6